PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy

Area of Science:

• Cardiology
• Pharmacology
• Genetics

Background:

• Atherosclerotic cardiovascular disease (ASCVD) is a leading global cause of death.
• Low-density lipoprotein cholesterol (LDL-C) is a primary driver of ASCVD.
• Despite statin therapy, significant residual cardiovascular risk persists.

Purpose of the Study:

• To evaluate the role of proprotein convertase subtilisin/kexin-type 9 (PCSK9) monoclonal antibodies (mAbs) in managing ASCVD.
• To analyze recent trial data for optimizing PCSK9-mAb use in high-risk populations.
• To inform clinical practice guidelines regarding PCSK9-mAb therapy.

Main Methods:

• Review and analysis of prespecified data from randomized controlled trials involving PCSK9-mAbs (alirocumab, evolocumab).
• Assessment of LDL-C reduction and impact on recurrent ASCVD events.
• Comparison with existing clinical practice guidelines and scientific statements.

Main Results:

• PCSK9-mAbs, in combination with statins, reduce LDL-C by up to 60%.
• These mAbs significantly decrease the risk of recurrent ASCVD events in stable and acute coronary syndrome populations.
• Recent analyses and guideline updates support an expanded role for PCSK9-mAbs in select high-risk groups.

Conclusions:

• PCSK9-mAbs represent a breakthrough therapy for very high-risk ASCVD patients.
• Personalized approaches to PCSK9-mAb therapy can maximize value and cost-effectiveness.
• Ongoing research investigates long-term safety, acute setting use, and novel PCSK9 inhibitors like inclisiran.